Replies to post #345675 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

One point on censor numbers.

The "heavy censoring" was 26 on the Optune arm vs 13 on the SOC arm. In a trial randomized 2-1. [I am talking patients censored for reasons other than being alive and actively followed at EOT]

So 39 of 695 with balanced censors.

In the DCVax-L trial we have at least 8, but the actual number is unknown as NWBO did not release the full numbers. I would not be surprised if the actual number in the DCVax-L trial is around 12 or so. In a trial half the size as Optune's.

Yes, Optune's trial was poor quality in various ways. We can all agree.

[learningcurve2020]

Looks like nobody preparing for the rug pull. Retail only sees the share price and rarely pays attention to the market cap. It’s already very lofty up here.

[flipper44]

You need to look at more than the table. You were right when you first stated there was heavy unequal censoring between arms in the Optune trial, but you were wrong when you relied upon one table to contradict yourself. “You really show your lack of understanding” statistical manipulation when you practice tunnel vision. Disappointing.

Furthermore, at one point you were pushing to limit the damage to Optune’s unsubstantiated five year stats. I did not say bad five year stats were inconsistent with a bad trial, I was instead calling you on blowing off other matters. I did not misunderstand the stats, you just took a five.